• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2017 Fiscal Year Final Research Report

Role of tumor-derived semaphorin 3A in the development of cancer pain

Research Project

  • PDF
Project/Area Number 15K08682
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Pain science
Research InstitutionNigata University of Phermacy and Applied Life Sciences

Principal Investigator

Maeda Takehiko  新潟薬科大学, 薬学部, 教授 (50271010)

Co-Investigator(Kenkyū-buntansha) 山田 大祐  新潟薬科大学, 薬学部, 助手 (50733680)
川原 浩一  新潟薬科大学, 薬学部, 准教授 (10347015)
Project Period (FY) 2015-04-01 – 2018-03-31
Keywordsセマフォリン3A / がん性疼痛 / mTOR / がん幹細胞 / 薬剤抵抗性
Outline of Final Research Achievements

Elucidation of potential therapeutic targets for bone cancer pain would contribute to relief of the intractable and unbearable pain. We used microarray analysis to reveal upregulation of semaphorin 3A (Sema3A) in the model mice for bone cancer pain. Knockdown of Sema3A and inhibition of Sema3A cellular signaling attenuated the tumor growth and the development of the pain. These results suggest that Sema3A is a potential therapeutic target molecule for the development of bone cancer pain.

Free Research Field

薬理学

URL: 

Published: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi